Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sci Ord Sh (NQ: WVE )

5.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 545,679
Open 5.890
Bid (Size) 5.900 (154)
Ask (Size) 5.920 (8)
Prev. Close 5.900
Today's Range 5.800 - 6.050
52wk Range 3.150 - 7.670
Shares Outstanding 98,983,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+10.49%
+10.49%
1 Month
+12.17%
+12.17%
3 Month
+56.50%
+56.50%
6 Month
+7.47%
+7.47%
1 Year
+60.76%
+60.76%

More News

Read More
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
WAVE Life Sciences's Earnings Outlook
Via Benzinga
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Earnings Scheduled For March 6, 2024
Via Benzinga
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
$16.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Via MarketBeat
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.